Meda rejects revised offer from Mylan

by The Associated Press

Swedish pharmaceutical company Meda says it has rejected another offer from U.S. generic drugmaker Mylan Inc.

Meda says its board decided to reject a revised Mylan proposal because the deal lacks support from Meda's largest shareholder, which the did not name in a brief statement. It also says the board turned down the offer due to a strong belief in Meda's potential as a stand-alone company.

Meda says all contact between the companies has ended with no further actions. The Swedish company also rebuffed an approach from Mylan earlier this month.

Mylan representatives did not immediately return a call seeking comment.

Meda's products include the eczema treatment Elidel and the antiseptic Betadine. It says its products are sold in more than 120 countries.

Mylan is based in Canonsburg, Pa.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Indian drugs group eyes $5 bn Swedish deal

May 31, 2013

Indian group Sun Pharmaceutical Industries is in talks to buy leading Swedish drugmaker Meda AB in what could result in a $5 billion takeover, the Wall Street Journal reported on Friday.

US drug firm Mylan to buy Indian firm for $1.6 bn

Feb 27, 2013

US generic drugs specialist Mylan said Thursday it would buy a unit of India's pharma firm Strides Arcolab for $1.6 billion, boosting its presence in the high-growth injectable drugs market.

US drugs firm Mylan completes $1.75 bln India buyout

Dec 05, 2013

US generic drug specialist Mylan said Thursday it had completed its $1.75 billion acquisition of a unit of India's Strides Arcolab, boosting its presence in the high-growth injectable drugs market.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

Oct 24, 2014

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments